Across TCGA pan-cancer cohorts, LINC01872 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LINC01872’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01872 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01872 is over-expressed in tumor.
KIRC and KIRP are the cancer types where LINC01872 tumor–normal differential expression is most reproducible.